A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia-Reference-Cited by-同舟云学术

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

Published:2021-11 Issue:11 Volume:21 Page:766-774
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Cheung Matthew C.,Mittmann Nicole,Owen Carolyn,Abdel-Samad Nizar,Fraser Graeme A.M.,Lam Selay,Crump Michael,Sperlich Catherine,van der Jagt Richard,Prica Anca,Couban Stephen,Woyach Jennifer A.,Ruppert Amy S.,Booth Allison M.,Mandrekar Sumithra J.,McDonald Gail,Shepherd Lois E.,Yen Hope,Chen Bingshu E.,Hay Annette E.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference28 articles.

1. Chronic lymphocytic leukaemia;Kipps;Nat Rev Dis Primers,2017

2. Society A.C. Cancer Facts & Figures 2019. American Cancer Society. https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/about/key-statistics.html. Published 2019. Accessed April 20, 2019, 2019.

3. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies;Advani;J Clin Oncol,2013

4. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia;Burger;N Engl J Med,2015

5. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL;Woyach;N Engl J Med,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness of Screening to Identify Pre-Diabetes and Diabetes in the Oral Healthcare Setting;Endocrines;2022-12-01

2. Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study;Frontiers in Oncology;2022-11-21

3. A systematic review of economic evaluations for the pharmaceutical treatment of chronic lymphocytic leukemia and acute myeloid leukemia;Expert Review of Hematology;2022-09-02

4. Bruton's Tyrosine Kinase Inhibitors for the Treatment of Waldenström's Macroglobulinaemia: A Canadian Perspective;Oncology & Haematology;2021